Paradromics
PrivateLast Round
Strategic
Feb 12, 2025
Total Funding Raised
$84.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Paradromics operates in Healthcare & Life Sciences and is based in Austin, Texas. Its latest recorded funding round was a Strategic round in February 2025.
Paradromics is a neurotechnology company that develops advanced brain-computer interface technology to enhance data transmission rates between the brain and machines, facilitating high-volume, bidirectional data streaming for patients with neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Paradromics Comparables
Compare Paradromics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bitfinex | 89% | |
| Precision Neuroscience | 87% | |
| Neuralink | 86% |
For institutional investors. Book with your work email.
Paradromics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 12, 2025 | ||||
| Series A | May 18, 2023 | ||||
| Grant | Oct 14, 2021 | ||||
| Seed | Jul 22, 2021 | ||||
| Seed | Jun 11, 2018 | ||||
Grant | Jul 10, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Paradromics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loup Funds | Seed |
| National Institute of Mental Health | Grant |
| Fusion Fund | Seed |
| Dolby Family Ventures | Seed, Strategic, Series A |
| IT-Farm Corporation | Seed, Strategic |
| NIH RADx | Grant |
| Tech-Synergy | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 39% MoM.
- Mar 18, 2026
Launched an academic collaboration programme to advance BCI technology.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 20, 2026
Paradromics is developing high-data-rate BCIs to restore and enhance human capabilities, while collaborating with Siemens Healthineers on a multimodal imaging platform for implantable BCIs in Texas as of Oct 20th '26.
- is_developingOct 19, 2026
Paradromics hopes to develop imaging protocols with Siemens Healthineers that span the implantation process, from candidacy assessment and neural target identification through surgical planning, navigation and validation, using MRI, CT and vascular scans.
- is_developingOct 19, 2026
On Oct 19th '26, Paradromics teams up with Siemens Healthineers to develop scalable BCI imaging protocols using MRI, CT, and vascular scans across the implantation process.
- is_developingOct 19, 2026
Paradromics intends to develop an optimized end-to-end imaging package with Siemens Healthineers, combining MRI, functional MRI, vascular imaging, and CT for brain mapping, surgical planning, and automated analysis.
- is_developingOct 19, 2026
Paradromics is collaborating with Siemens Healthineers to develop an advanced multimodal imaging platform that supports the growing clinical use of implantable brain-computer interfaces in Texas on Oct 19th '26.
For institutional investors. Book with your work email.
Paradromics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Paradromics's valuation, stock price, and market status.
Is Paradromics a public or private company?
Paradromics is a private company.
What is the current stock price of Paradromics?
Paradromics is a private company, so its shares have no public market price. Caplight tracks Paradromics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Paradromics worth (valuation)?
Valuation information for Paradromics is not publicly available.
Can I buy Paradromics stock?
Paradromics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Paradromics's last funding round?
Paradromics's most recent funding round was Strategic on February 12, 2025.
Who are the main investors in Paradromics?
Key investors in Paradromics include NIH RADx, Tech-Synergy, Synergy Ventures, Arkitekt Ventures, Prime Movers Lab.
Will Paradromics IPO soon?
No public IPO plans have been announced for Paradromics.
How can I track Paradromics secondary market activity?
Caplight tracks bids, offers, and trades in Paradromics's shares on secondary markets.